USFDA observations at three facilities
Form 483s with 5 observations at Bachupalli Biologics, 7 at Mirfield API site and Srikakulam facility.
high · management_commentary
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
North America pricing pressure
Revenue declined 13% YoY due to price erosion and weaker Lenalidomide sales; management acknowledged pressure.
medium · management_commentaryPSAI margin collapse
PSAI margins dropped to 18% from 30% last year due to lower operating leverage and unfavorable mix.
medium · data_observation